Search
Lepu Medical Achieves Milestone: First Subject Dosed in Phase II Clinical Trial of MWN105 Injection for Obesity Treatment
2025-09-04 /
Read about 0 minute
Author：小编
Lepu Medical has announced a significant advancement in its research pipeline, as its subsidiary Minwei Biotech has successfully dosed the first subject in the Phase II clinical trial of its innovative drug, MWN105 Injection. This drug, designed to treat overweight and obesity, represents a groundbreaking triple agonist targeting the GLP-1/GIP/FGF21 receptors, and holds global intellectual property rights. Preclinical studies have demonstrated MWN105 Injection's promising efficacy and safety profile.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
